Patient-derived xenografts and matched cell lines identify pharmacogenomic vulnerabilities in colorectal cancer
Articolo
Data di Pubblicazione:
2019
Citazione:
Patient-derived xenografts and matched cell lines identify pharmacogenomic vulnerabilities in colorectal cancer / L. Lazzari, G. Corti, G. Picco, C. Isella, M. Montone, P. Arcella, E. Durinikova, E.R. Zanella, L. Novara, F. Barbosa, A. Cassingena, C. Cancelliere, E. Medico, A. Sartore-Bianchi, S. Siena, M.J. Garnett, A. Bertotti, L. Trusolino, F. Di Nicolantonio, M. Linnebacher, A. Bardelli, S. Arena. - In: CLINICAL CANCER RESEARCH. - ISSN 1557-3265. - 25:20(2019 Aug 02), pp. 6243-6259. [10.1158/1078-0432.CCR-18-3440]
Abstract:
Patient-derived xenograft (PDX) models accurately recapitulate the tumor of origin in terms of histopathology, genomic landscape, and therapeutic response, but some limitations due to costs associated with their maintenance and restricted amenability for large-scale screenings still exist. To overcome these issues, we established a platform of 2D cell lines (xeno-cell lines, XLs), derived from PDXs of colorectal cancer (CRC) with matched patient germline gDNA available.
Tipologia IRIS:
01 - Articolo su periodico
Elenco autori:
L. Lazzari, G. Corti, G. Picco, C. Isella, M. Montone, P. Arcella, E. Durinikova, E.R. Zanella, L. Novara, F. Barbosa, A. Cassingena, C. Cancelliere, E. Medico, A. Sartore-Bianchi, S. Siena, M.J. Garnett, A. Bertotti, L. Trusolino, F. Di Nicolantonio, M. Linnebacher, A. Bardelli, S. Arena
Link alla scheda completa: